Aether Industries Limited — Q4 FY26 earnings call

Call held 15 May 2026

Management summary

Aether Industries reported strong FY26 results with significant revenue and EBITDA growth, driven by robust pricing and strategic expansions. While Q4 saw a sequential decline in financials due to one-off items and logistical issues, the company is confident in its growth trajectory, supported by new product commercialization from Site 5, R&D expansion, and a strategic shift towards higher-margin CRAMS/CEM business models.

Highlights

  • FY26 Consolidated Revenue grew 38% YoY to INR11,601 million.

  • FY26 EBITDA grew 53% YoY to INR3,547 million, with margin expanding to 31% from 28%.

  • Working capital cycle reduced to 179 days from 194 days as of March 31, 2025.

  • Site 4 revenue grew 4x from INR50 crores to INR220 crores, now representing 21% of total sales.

  • 3 new large-scale manufacturing products from Site 5 are expected to be commissioned by May end or early June 2026.

Concerns

  • Q4 FY26 Consolidated Revenue declined QoQ to INR3,051 million from INR3,188 million in Q3 FY26.

  • Q4 FY26 EBITDA declined QoQ to INR814 million from INR1,099 million in Q3 FY26.

  • Q4 FY26 PAT declined QoQ to INR540 million from INR645 million in Q3 FY26.

  • Q4 results were impacted by a INR70 million inventory write-off due to a fire and INR10 million in year-end provisions.

Key financials

3 periods

Headline

  • Working Capital Cycle
    179 days

Q4 FY26

  • Consolidated Revenue
    ₹3,051 Cr
  • EBITDA
    ₹814 Cr
  • PAT
    ₹540 Cr

FY26

  • Consolidated Revenue
    ₹11,601 Cr
    YoY +38%
  • EBITDA
    ₹3,547 Cr
    YoY +53%
  • EBITDA Margin
    31%
  • PAT
    ₹2,195 Cr
    YoY +39%
  • PAT Margin
    19%
  • Cash Flow from Operations
    ₹1,424 Cr
    YoY +42.4%

What they filed

Q1 FY27: revenue up 27.2%, net profit up 34.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue199 220 240 257 280 +41%319 +45%305 +27%327 +27%
EBITDA54 65 80 81 88 +63%112 +72%83 +4%103 +27%
Net profit35 43 50 47 54 +54%64 +49%54 +8%63 +34%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Large-Scale Manufacturing (Q4 FY26)
    43% Sales Contribution
  • CRAMS and CEM (Q4 FY26)
    55% Revenue Contribution
  • Site 4 (FY26)
    ₹220 Cr Revenue3.4× Revenue Growth21% Total Sales Contribution
  • Pharma plus Agro (FY26)
    46% Total Sales Contribution
  • Material Science (FY26)
    17% Total Sales Contribution

Capital allocation

high confidence
  • Capex ₹3,000 Cr
    • Primarily for Site 5 and new R&D site
    The capex in financial year '27 will be primarily for Site 5 and also for the new R&D site, which is already progressing well.
  • Debt Debt disclosed
    So we will now be requiring some debt. We already started speaking with the bankers, and you will see the debt coming up -- increasing a bit in the current year. And it will gradually increase. It's not that it will increase in one go. We'll be taking the debt for the requirements of the project progress.

Guidance & targets

Profitability

  • EBITDA Margin Profitability · FY27 · High confidence 29-30%
    We hope to keep margins stable between the 29% to 30% EBITDA margins as well as in the PAT around 19% to 20%.

    — Kushal Doshi

  • PAT Margin Profitability · FY27 · High confidence 19-20%

    — Kushal Doshi

Business Mix

  • CRAMS and Contract Exclusive Manufacturing Sales Contribution Business Mix · FY30 · High confidence 70%+
    We are very confident of achieving our vision of 70% of revenues coming from CRAMS and contract exclusive manufacturing business models by fiscal year '30.

    — Aman Desai

  • CRAMS and CEM vs LSM Revenue Mix Business Mix · next 3-4 years · High confidence 70% CRAMS/CEM, 30% LSM
    FY28, but what we're looking over the next 3 to 4 years is 70% of the revenue coming from CRAMS and CEM and 30-odd percent coming from large-scale manufacturing.

    — Kushal Doshi

Market Opportunity

  • Semiconductor Materials Opportunity Market Opportunity · by 2030 · High confidence Tripling
    We see this opportunity tripling by 2030.

    — Rohan Desai

R&D

  • Interim R&D Expansion Commercialization R&D · Q2 fiscal · High confidence Commercialization
    We expect the commercialization of these new fume hoods and NMR machines to begin from Q2 onwards of this fiscal.

    — Aman Desai

  • New R&D Plant Commissioning R&D · Q2 FY28 · High confidence Commissioning
    The construction of the entirely new R&D plant and the new R&D wing that we are also undergoing is also progressing on schedule and is completed -- expected to be commissioned in second quarter of FY28.

    — Aman Desai

Capacity

  • Site 5 Phase 1 Commercialization Capacity · this financial year · High confidence Commercialization
    And the most important thing, I think, will be the commencement of commercialization of Site 5 in Phase 1, where we look to commercialize this entire phase in this financial year.

    — Kushal Doshi

Working Capital

  • Working Capital Cycle Working Capital · end of FY27 · High confidence 160 days (targeting 150 days)

    From 179 days today

    So we see that by end of this year this financial year '27, we'll be again having a healthy working capital reduction, which we expect to be around 160 days at least. Our try is to bring it down to 150 days, but 160 days is what we are expecting currently to be.

    — Faiz Nagariya

Efficiency

  • Site 5 Asset Turns Efficiency · High confidence 1.5 to 1.75
    Asset turn for Site 5 is being targeted between 1.5 to 1.75.

    — Faiz Nagariya

Competencies

  • 10x10 Competencies Competencies · end of this year · High confidence 10x10

    From 9x9 today

    We started with 8x8. I think we are already at about, say, 9x 9, if you will, and 10x 10 should be for sure within the end of this year.

    — Aman Desai

What to watch in Q1 FY27

Site 5 New Product Commercialization

next quarter (Q1 FY27)
Current 3 new LSM products (2 pharma, 1 agrochemical) from Site 5 to be commissioned by May end/early June.
Target Commercial production started for new products.

Why it matters

Site 5 is a major growth driver, and commercialization is key to realizing its potential.

There are 3 new large-scale manufacturing products, 2 in pharmaceutical and one agrochemical from Site 5, which will be commissioned by May end or starting of June 1st week.

Risks & concerns

  • Fire Incidents

    medium

    Two fire incidents occurred (Nov 2023 and March 2026). The March 2026 incident resulted in a INR70 million inventory write-off, though management stated it was a non-event with minimal loss and caused by neighboring premises.

    Both acknowledged

Q&A highlights

7 direct
Future Business Model & Moat Direct
We hope it continues to stay the same, but only do it for the lack of a better word, bigger and better. And -- but at the same time, being fundamentally grounded in the foundational premise of the company, which is what we talked about.

Management emphasizes continuity of core strategy (innovation, chemistry, technology) but at a larger scale, indicating confidence in their foundational approach.

Asked by Sajal Kapoor

Impact of Currency Prices on Exports/Margins Partial
So we are selling to Indian subsidiaries and then they are exporting the same to various part of the world instead of us selling into the U.S. basically. But now that things have been resolved, and I think in the quarters to come, you will see the exports growing and coming back to 50%, 60% of our total top line.

Asked by Amay Sharda

Q4 Margin Decline Reasons Direct
The major reason was the INR70 million inventory write-off on account of fire, which took place at the external warehouse. Also in the third quarter, there was FLOP claim income, which was part of the revenues from other operations, which was not there in the fourth quarter.

Asked by Nikunj Gupta

Competitive Edge in Advanced Materials Direct
And so combining the innovations in chemistry and technology that we bring in into the processes which are truly new age and modern and economies of scale of anything that we do and then being strategically located in India provides us firmly a preferred seat at the table.

Asked by Jay Shah

Working Capital Reduction Targets Direct
So we see that by end of this year this financial year '27, we'll be again having a healthy working capital reduction, which we expect to be around 160 days at least. Our try is to bring it down to 150 days, but 160 days is what we are expecting currently to be.

Asked by Abhijit Akella

LSM Revenue Decline in Q4 Direct
I'm not sure how you got the price erosion, but what we have seen is a price increase. There's been a volume decrease in LSM in Q4, which, as I mentioned to you earlier was that on account of the logistics issues, which has then been shipped to the respective customers in the months of April and May, which were done at a higher price.

Asked by Prateek Shrivastava

Site 5 Production Blocks & Land Bank Direct
We have already completed the construction of 4 blocks. Two blocks are already ready to run. So water trials and solvent trials are ongoing... Total 16 production blocks can come in on Site 5... Total land bank, it's 45 -- 46 acres, and we'll have 20 production blocks coming in more or less as per our plan as of today, our plan in this Site 5.

Asked by Rohit Ohri

10x10 Competencies Timeline Direct
We started with 8x8. I think we are already at about, say, 9x 9, if you will, and 10x 10 should be for sure within the end of this year.

Asked by Rohit Ohri

3 min read 7 chapters

Detailed narrative

Strong FY26 Performance Despite Q4 Headwinds

Aether Industries reported a robust FY26, with consolidated revenue growing 38% YoY to INR11,601 million and EBITDA increasing 53% YoY to INR3,547 million. EBITDA margin expanded by 300 basis points to 31%. However, Q4 FY26 saw a sequential decline in revenue to INR3,051 million and PAT to INR540 million, primarily due to a INR70 million inventory write-off from a fire incident and the absence of a one-off INR200 million FLOP claim income recognized in Q3.

Strategic Capacity Expansion and Product Commercialization

The company is on track with its ambitious expansion plans, with FY26 capex at INR3,838 million and an expected INR3,000-3,500 million for FY27, mainly for Site 5 and the new R&D site. Site 5 is a major focus, with 3 new large-scale manufacturing products (2 pharma, 1 agrochemical) expected to be commissioned by May end or early June 2026. The total Site 5 plan includes 20 production blocks over a 45-46 acre land bank, with 2 blocks already ready to run.

R&D Infrastructure and Innovation Pipeline

Aether is significantly enhancing its R&D capabilities, with an interim expansion including 2 new labs, 18 fume hoods, and a 400 MHz NMR machine, expected to commercialize from Q2 FY27. A new, larger R&D plant is under construction, slated for commissioning in Q2 FY28, which will double current R&D strength with 15 new labs and ~140 fume hoods. This investment supports a robust pipeline of new projects, particularly in material science and oil & gas sectors.

Shifting Business Mix Towards CRAMS and CEM

The company's strategic vision is to achieve 70% of revenues from CRAMS (Contract Research and Manufacturing Services) and CEM (Contract Exclusive Manufacturing) business models by FY30. In Q4 FY26, LSM contributed 43% of sales, while CRAMS and CEM together accounted for 55%. Management expects this proportion to increase further in FY27, driven by new CRAMS projects and the commercialization of Site 5.

Favorable Pricing Environment and Working Capital Efficiency

Aether experienced strong pricing in its large-scale manufacturing segment in Q4, with prices increasing over 20% YoY and 18% QoQ, which are expected to be sustainable for the medium term. The company also demonstrated improved working capital management, reducing its overall working capital cycle to 179 days as of March 31, 2026, from 194 days in the previous year. Further reduction to 160 days, targeting 150 days, is expected by the end of FY27.

Global Market Opportunities and Competitive Advantage

Management highlighted significant opportunities in global markets, particularly in material sciences and oil & gas, with the semiconductor materials opportunity expected to triple by 2030. Aether's competitive advantage is attributed to its strong R&D capabilities, chemical engineering expertise, economies of scale, and India's cost-competitive strategic location, enabling it to compete effectively against global players like BASF and Lanxess.

Leadership and Competency Expansion

Aether is strengthening its leadership team, including the addition of Mr. Guenter Stevens for global technology and business development, bringing expertise in material sciences and application testing. The company is also progressing towards its '10x10' competencies goal, currently at '9x9' and aiming to reach '10x10' by the end of 2026, signifying a continuous expansion of its technological and chemical capabilities.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Chemicals earnings calls